MAPK3 and prostate carcinoma: As a conclusion, one may say, that the treatment of androgen-independent prostate cancer cells with SAM leads to the downregulation of the ERK1/2 pathway and STAT3 pathways which both are involved in cell survival, proliferation, migration and invasion of cancer cells.